Physician profile
Thomas Scheuerman
NPI 1033155627
$883.03
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $621 · 2020: $262.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $333.29 | 2019-2020 | |
| Insmed, INC. | $178.84 | 2019-2020 | |
| Genentech USA, INC. | $171.55 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $100.22 | 2019 | |
| Novartis Pharmaceuticals Corporation | $20.69 | 2019 | |
| Philips North America LLC | $18.13 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $17.60 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.64 | 2019 | |
| Grifols USA, LLC | $14.04 | 2020 | |
| Genzyme Corporation | $14.03 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Scheuerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.